Targeting Beta-Globin Gene Mutations: CRISPR/Cas9 in Beta-Thalassemia Therapy
Beta-thalassemia, a genetic blood disorder, is caused by mutations in the beta-globin gene. كريسبر/كاس9, a gene-editing technology, offers a promising approach for correcting these mutations and restoring normal hemoglobin production. This article analyzes the potential of CRISPR/Cas9 in beta-thalassemia therapy, exploring its advantages, القيود, and future implications.












